A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease

Grants and Contracts Details

StatusFinished
Effective start/end date11/21/16 → 3/17/22

Funding

  • Novartis (domestic): $588,132.00